PolTREG will produce its PTG-007 therapy with blood received from patients selected by the UCC, and deliver the finished product to UCC for a payment. Patients will then be injected with the preparation – derived from their own blood – at UCC.

While PTG-007 is not yet on the market, it is available in Poland under a hospital exemption. It has shown a strong safety and efficacy profile in an earlier Phase 1/2 clinical study.

PolTREG has the most advanced pipeline of Treg candidate therapies, which it produces in its own state-of-the-art manufacturing facility. It is the only company developing all available modalities of Treg therapies for a wide range of auto-immune diseases, including naturally occurring polyclonal T-cells and several types of next-generation engineered T-cells. 

PolTREG has 17 years of experience in treating patients with type-1 diabetes as well as multiple sclerosis, a period in which it has treated 100 patients.